DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Beta-lactam and Beta-lactamase Inhibitors Market

Global Beta-lactam and Beta-lactamase Inhibitors Market Opportunities and Forecast 2020-2027

  • DLR2369
  • 12 October, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Beta-lactam and Beta-lactamase Inhibitors Market, By Route Of Administration (Oral, Intravenous, Others), By Disease (Urinary Tract Infection (excluding cUTI), Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, Other), By Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, Combination), and opportunities and forecast 2020-2027

Beta-lactam and Beta-lactamase Inhibitors Market Overview

Beta-lactam and beta-lactamase inhibitors are natural, semi-synthetic, or synthetic chemical substances. Bacteria and protozoans are inhibited by them. The global Beta-lactam and Beta-lactamase Inhibitors market is expected to grow at significant rate in the forthcoming years.
 
The market for Beta-lactam and Beta-lactamase Inhibitors is expected to develop due to increased consumption in low and middle-income countries (LMICs) and an increase in the prevalence of infectious disorders. In addition, the market is being bolstered by the development of novel techniques for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections, as well as a high number of clinical trials.
 
On the downside, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitorsand the time taken for the regulatory approval are some reasons that expected to hamper the growth of the market. Besides this, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are anticipated to create significant lucrative opportunities for the market players.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered By Route Of Administration, Disease, Drug Class, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.


Covid-19 Impact on Beta-lactam and Beta-lactamase Inhibitors Market
 
In addition, the current Beta-lactam and Beta-lactamase Inhibitors Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Beta-lactam and Beta-lactamase Inhibitors Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Beta-lactam and Beta-lactamase Inhibitors Market Segment Overview


Based on the Drug Class, the Cephalosporin segment grasp the major share in the market and is estimated to continue this trend during forecast period. This is mostly due to its broad-spectrum activity and the introduction of next-generation cephalosporins that can combat antimicrobial resistance. In addition, it treats infections caused by a variety of germs. As a result, cephalosporin is in high demand among healthcare practitioners and patients, boosting the global market's growth. According to Disease, the Complicated Intra-Abdominal Infections (cIAI) is the largest segment in the market. This is attributed to the rise in burden of sepsis and rapid increase in mortality rate with greater disease severity across the world.

Beta-lactam and Beta-lactamase Inhibitors Market, By Route Of Administration
·       Oral
·       Intravenous
·       Others

Beta-lactam and Beta-lactamase Inhibitors Market, By Disease
·       Urinary Tract Infection (excluding cUTI)
·       Respiratory Infection
·       Skin Infection
·       Complicated Urinary Tract Infection (cUTI)
·       Complicated Intra-Abdominal Infections (cIAI)
·       Nosocomial Pneumonia
·       Blood Stream Infection
·       Other

Beta-lactam and Beta-lactamase Inhibitors Market, By Drug Class
·       Penicillin
·       Cephalosporin
·       Carbapenem
·       Monobactam
·       Combination

Beta-lactam and Beta-lactamase Inhibitors Regional Overview

Geographically, LAMEA is expected to show the highest growth during the forecast period. This is due to the easy accessibility of beta-lactam and beta-lactamase inhibitors over-the-counter as well as there are no regulation or restrictions on their use in this region. On the other hand, Asia-Pacific is another major region for market. This is because of the increase in consumption of beta-lactam and beta-lactamase inhibitors, easy accessibility of these drugs, and rise in sale of beta-lactam and beta-lactamase inhibitors without prescription.

Beta-lactam and Beta-lactamase Inhibitors Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Beta-lactam and Beta-lactamase Inhibitors Market, Key Players

·       Abbott Laboratories
·       Allergan Plc.
·       F. Hoffmann-La Roche Ltd.
·       GlaxoSmithKline plc
·       Merck & Co. Inc.
·       Mylan N.V.
·       Novartis International AG (Sandoz)
·       Pfizer Inc.
·       Sanofi
·       Teva Pharmaceutical Industries Ltd.



Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Beta-lactam and Beta-lactamase Inhibitors market during the forecast period?

A. The Beta-lactam and Beta-lactamase Inhibitors market is expected to record a CAGR of ~ 2 % during the forecast period.

Q2. What are the driving factors for the Beta-lactam and Beta-lactamase Inhibitors market?

A. Increased consumption in low and middle-income countries (LMICs) and an increase in the prevalence of infectious disorders are some major factors that boosting the growth of the Beta-lactam and Beta-lactamase Inhibitors market.

Q3. What are the restraining factors for the Beta-lactam and Beta-lactamase Inhibitors market?

A. The development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval are some major factors that hamper the growth of the global Beta-lactam and Beta-lactamase Inhibitors market.

Q4. Which segment is projected to hold the largest share in the Beta-lactam and Beta-lactamase Inhibitors Market. ?

A. The Cephalosporin segment is projected to hold the largest share in the Beta-lactam and Beta-lactamase Inhibitors Market.

Q5. Which are the prominent players in the Beta-lactam and Beta-lactamase Inhibitors Market?

A. Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. are some key players in the Beta-lactam and Beta-lactamase Inhibitors Market.
Beta-lactam and Beta-lactamase Inhibitors Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Route Of Administration
        • 5.2.1. Oral
        • 5.2.2. Intravenous
        • 5.2.3. Others
      • 5.3. Market Analysis, Insights and Forecast – By Disease
        • 5.3.1. Urinary Tract Infection (excluding cUTI)
        • 5.3.2. Respiratory Infection
        • 5.3.3. Skin Infection
        • 5.3.4. Complicated Urinary Tract Infection (cUTI)
        • 5.3.5. Complicated Intra-Abdominal Infections (cIAI)
        • 5.3.6. Nosocomial Pneumonia
        • 5.3.7. Blood Stream Infection
        • 5.3.8. Other
      • 5.4. Market Analysis, Insights and Forecast – By Drug Class
        • 5.4.1. Penicillin
        • 5.4.2. Cephalosporin
        • 5.4.3. Carbapenem
        • 5.4.4. Monobactam
        • 5.4.5. Combination
      • 5.5. Market Analysis, Insights and Forecast – By Region
        • 5.5.1. North America
        • 5.5.2. Europe
        • 5.5.3. Asia Pacific
        • 5.5.4. Latin America, Middle East and Africa

      6. North America Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Route Of Administration
        • 6.2.1. Oral
        • 6.2.2. Intravenous
        • 6.2.3. Others
      • 6.3. Market Analysis, Insights and Forecast – By Disease
        • 6.3.1. Urinary Tract Infection (excluding cUTI)
        • 6.3.2. Respiratory Infection
        • 6.3.3. Skin Infection
        • 6.3.4. Complicated Urinary Tract Infection (cUTI)
        • 6.3.5. Complicated Intra-Abdominal Infections (cIAI)
        • 6.3.6. Nosocomial Pneumonia
        • 6.3.7. Blood Stream Infection
        • 6.3.8. Other
      • 6.4. Market Analysis, Insights and Forecast – By Drug Class
        • 6.4.1. Penicillin
        • 6.4.2. Cephalosporin
        • 6.4.3. Carbapenem
        • 6.4.4. Monobactam
        • 6.4.5. Combination
      • 6.5. Market Analysis, Insights and Forecast – By Country
        • 6.5.1. U.S.
        • 6.5.2. Canada

      7. Europe Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Route Of Administration
        • 7.2.1. Oral
        • 7.2.2. Intravenous
        • 7.2.3. Others
      • 7.3. Market Analysis, Insights and Forecast – By Disease
        • 7.3.1. Urinary Tract Infection (excluding cUTI)
        • 7.3.2. Respiratory Infection
        • 7.3.3. Skin Infection
        • 7.3.4. Complicated Urinary Tract Infection (cUTI)
        • 7.3.5. Complicated Intra-Abdominal Infections (cIAI)
        • 7.3.6. Nosocomial Pneumonia
        • 7.3.7. Blood Stream Infection
        • 7.3.8. Other
      • 7.4. Market Analysis, Insights and Forecast – By Drug Class
        • 7.4.1. Penicillin
        • 7.4.2. Cephalosporin
        • 7.4.3. Carbapenem
        • 7.4.4. Monobactam
        • 7.4.5. Combination
      • 7.5. Market Analysis, Insights and Forecast – By Country
        • 7.5.1. UK
        • 7.5.2. Germany
        • 7.5.3. France
        • 7.5.4. Italy
        • 7.5.5. Spain
        • 7.5.6. Russia
        • 7.5.7. Rest of Europe

      8. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Route Of Administration
        • 8.2.1. Oral
        • 8.2.2. Intravenous
        • 8.2.3. Others
      • 8.3. Market Analysis, Insights and Forecast – By Disease
        • 8.3.1. Urinary Tract Infection (excluding cUTI)
        • 8.3.2. Respiratory Infection
        • 8.3.3. Skin Infection
        • 8.3.4. Complicated Urinary Tract Infection (cUTI)
        • 8.3.5. Complicated Intra-Abdominal Infections (cIAI)
        • 8.3.6. Nosocomial Pneumonia
        • 8.3.7. Blood Stream Infection
        • 8.3.8. Other
      • 8.4. Market Analysis, Insights and Forecast – By Drug Class
        • 8.4.1. Penicillin
        • 8.4.2. Cephalosporin
        • 8.4.3. Carbapenem
        • 8.4.4. Monobactam
        • 8.4.5. Combination
      • 8.5. Market Analysis, Insights and Forecast – By Country
        • 8.5.1. China
        • 8.5.2. India
        • 8.5.3. Japan
        • 8.5.4. Australia
        • 8.5.5. South East Asia
        • 8.5.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Route Of Administration
        • 9.2.1. Oral
        • 9.2.2. Intravenous
        • 9.2.3. Others
      • 9.3. Market Analysis, Insights and Forecast – By Disease
        • 9.3.1. Urinary Tract Infection (excluding cUTI)
        • 9.3.2. Respiratory Infection
        • 9.3.3. Skin Infection
        • 9.3.4. Complicated Urinary Tract Infection (cUTI)
        • 9.3.5. Complicated Intra-Abdominal Infections (cIAI)
        • 9.3.6. Nosocomial Pneumonia
        • 9.3.7. Blood Stream Infection
        • 9.3.8. Other
      • 9.4. Market Analysis, Insights and Forecast – By Drug Class
        • 9.4.1. Penicillin
        • 9.4.2. Cephalosporin
        • 9.4.3. Carbapenem
        • 9.4.4. Monobactam
        • 9.4.5. Combination
      • 9.5. Market Analysis, Insights and Forecast – By Country
        • 9.5.1. Brazil
        • 9.5.2. Saudi Arabia
        • 9.5.3. UAE
        • 9.5.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Abbott Laboratories
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Allergan Plc.
      • 10.6. F. Hoffmann-La Roche Ltd.
      • 10.7. GlaxoSmithKline plc
      • 10.8. Merck & Co. Inc.
      • 10.9. Mylan N.V.
      • 10.10. Novartis International AG (Sandoz)
      • 10.11. Pfizer Inc.
      • 10.12. Sanofi
      List of Figures

      Figure 1: Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Beta-lactam and Beta-lactamase Inhibitors Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934